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The t(8;14)(q24.1;q32), the cytogenetic hallmark of Burkitt’s lymphoma, is also found, but rarely, in cases of chronic
lymphocytic leukemia (CLL). Such translocation typically results in a MYC-IGH@ fusion subsequently deregulating
and overexpressing MYC on der 14q32. In CLL, atypical rearrangements resulting in its gain or loss, within or
outside of IGH@ or MYC locus, have been reported, but their clinical significance remains uncertain. Herein, we
report a 67 year-old male with complex cytogenetic findings of apparently balanced t(8;14) and unreported
complex rearrangements of IGH@ and MYC loci. His clinical, morphological and immunophenotypic features were
consistent with the diagnosis of CLL.
Interphase FISH studies revealed deletions of 11q22.3 and 13q14.3, and an extra copy of IGH@, indicative of
rearrangement. Karyotype analysis showed an apparently balanced t(8;14)(q24.1;q32). Sequential GPG-metaphase
FISH studies revealed abnormal signal patterns: rearrangement of IGH break apart probe with the 5’-IGH@ on
derivative 8q24.1 and the 3’-IGH@ retained on der 14q; absence of MYC break apart-specific signal on der 8q; and,
the presence of unsplit 5’-MYC-3’ break apart probe signals on der 14q. The breakpoint on 8q24.1 was found to be
at least 400 Kb upstream of 5’ of MYC. In addition, FISH studies revealed two abnormal clones; one with 13q14.3
deletion, and the other, with concurrent 11q deletion and atypical rearrangements. Chromosome microarray
analysis (CMA) detected a 7.1 Mb deletion on 11q22.3-q23.3 including ATM, a finding consistent with FISH results. While
no significant copy number gain or loss observed on chromosomes 8, 12 and 13, a 455 Kb microdeletion of uncertain
clinical significance was detected on 14q32.33. Immunohistochemistry showed co-expression of CD19, CD5, and CD23,
positive ZAP-70 expression and absence of MYC expression. Overall findings reveal an apparently balanced
t(8;14) and atypical complex rearrangements involving 3’-IGH@ and a breakpoint at least 400 Kb upstream of MYC,
resulting in the relocation of the intact 5’-MYC-3’ from der 8q, and apposition to 3’-IGH@ at der 14q. This case report
provides unique and additional cytogenetic data that may be of clinical significance in such a rare finding in CLL. It also
highlights the utility of conventional and sequential metaphase FISH in understanding complex chromosome
anomalies and their association with other clinical findings in patients with CLL. To the best of our knowledge, this is
the first CLL reported case with such an atypical rearrangement in a patient with a negative MYC expression.
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Chronic lymphocyctic leukemia (CLL) is the most com-
mon leukemia in the elderly with clinical presentation of
lymphocytosis, bone marrow involvement, lymphaden-
opathy, hepatosplenomegaly, complex cytogenetics and
heterogeneous clinical course [1]. Immunophenotypi-
cally, aberrant expression of CD5, CD20, CD22, CD23,
CD38, CD43 and CD79 is diagnostic or prognostic of
B-cells in CLL [2]. Common cytogenetic anomalies in-
clude deletion of 13q14.3 (most frequent) and/or 13q34,
deletion of 11q, deletion of 17p, trisomy 12 and IGH@
rearrangement [3].
While t(8;14)(q24.1;q32), the cytogenetic hallmark of
Burkitt’s lymphoma, is a primary genetic event found in
about 70-80% of cases, it is usually a rare secondary
anomaly in other B-cell disorders including CLL (about
0.2% to <1%) [4-8], lymphoblastic leukemia, DLBCL,
and in other lymphoma transforming into a more ag-
gressive disease [9]. In the latter, t(8;14) usually confers
favorable prognosis, while a more aggressive phenotype
and poor outcome are manifested when it is a part of a
complex chromosome complement [5,10].
In a typical t(8;14)(q24;q32) translocation, the MYC at
8q24.1 locus is spatiotemporally juxtaposed with the
3’-IGH@ locus on derivative 14q32 [11-15]. The IGH
transcription factory, about 2.5 Mb in size [12], localizes
the regulatory elements for MYC deregulation and vari-
able regions that promote translocation [13]. The IGH@
locus, is a hotspot for recombination and mutation of
immunoglobulin genes during B-cell maturation, pro-
cesses that usually promote translocations with oncogenic
potential [11]. Whereas the breakpoint on chromosome
14 is within the IGH@ locus, usually located within
the μ-gene, either within or adjacent to the variable
(V), joining (J), diversity (D, or switch (S) regions, but
other heavy-chain regions are occasionally involved [9].
While about 80% of translocations in Burkitt’s lymphoma
is typical and involve MYC and IGH@ (IG heavy chain)
[16], others are involved in variant partnership with other
IG chain loci; kappa light chain (IGK) at 2p12, or lambda
light chain (IGL) at 22q11.2 [16-18]. MYC is also
involved with IGH in DLBCL [18], TCR alpha/delta in
T-acute lymphoblastic leukemia/lymphoma, and IG
kappa and lambda chains in plasma cell myeloma
[18,19].
MYC is a proto-oncogene that encodes for a transcrip-
tion factor that regulates cell cycle progression, growth, dif-
ferentiation, apoptosis, survival and biosynthesis [4,6,20]. It
activates or represses transcription factories of other genes
(about 10%), transcription factors, and chromatin modify-
ing and remodeling complexes [20]. Rearrangements in-
volving MYC drive cells into lymphomagenesis often
through its deregulation and overexpression [5,11,12,21,22].
The oncogenic potential of MYC rearrangements isimplicated not only in the initiation of lymphomagenesis
but also in its transformation and progression of low-grade
lymphomas into a more advanced disease and an unfavor-
able outcome [5,17,18,21-23]. These findings suggest that
the level of deregulated MYC expression of different stages
of aberrant cellular maturation and differentiation may in-
fluence the neoplastic phenotype [9].
At 8q24.1 locus, translocation breakpoints are located
within or surrounding the MYC: regulatory region
within MYC, from exon 1 to intron 1, (Class I and most
common); transcription factor binding-site at or adjacent
to 5’-MYC (Class II); and long-range regions up to 100-
300 Kb or more upstream from an intact 5’-MYC-3’
(Class III) [15,16,20]. It has been suggested that aberrant
MYC expression is influenced by breakpoint location,
mutation within the translocated region, deletion of
regulatory elements, or transcription at cryptic sites
other than the usual P1 or P2 initiation start site (pro-
moter shift) [15,20,24]. Increased transcriptional activity
is observed in breakpoints within exon 1 and intron 1
(Class I) than when it occurs within the most common
breakpoint, 5’ from MYC exon 1 (Class II) [15]. Long-
range cis-acting enhancers regulate MYC expression
through chromatin looping bringing the enhancers in
close proximity to MYC [25,26], or through increased
distal enhancer activity utilizing preexisting loops [27].
Multiple genetic variants and SNPs, located in 1.5 Mb
“gene desert” regions 1, 2 and 3, up to 600 Kb upstream
of MYC, are associated with increased susceptibility to
prostate, colorectal, bladder, breast cancer, or chronic
lymphocytic leukemia [26-28]. Although reporter ex-
pression studies revealed that long-range enhancers and
other regulatory elements regulate MYC transcription,
the clinical significance of MYC rearrangements up-
stream of MYC remain unclear and a subject of bur-
geoning field of investigation [4].
To date, there are only very few reported cases of CLL
with apparently balanced t(8;14) and atypical rearrange-
ments [6,8], none of which exhibits abnormal FISH
signal patterns similar to what we detected in our pa-
tient. These abnormal patterns include: cryptic deletion
on 8q24.1 including MYC [6,8], gain of an extra copy of
MYC (+MYC) [4,5,29], or deletion of IGH@, usually
5’ [3,4,6,30,31]. The prognosis for these cases is also vari-
able, from indolent to transformed into a more aggressive
course.
Here we report a CLL case with complex cytogenetic
findings of deletions of 11q and 13q, in addition to the
apparently balanced t(8;14). We also present an undocu-
mented atypical complex rearrangements involving
3’-IGH@ and at least 400 Kb upstream of 5’-MYC, unre-
ported complex atypical rearrangements of IGH@ and
MYC loci that did not result in IGH-MYC fusion and no
subsequent MYC expression.
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Our patient is a 67 year-old Hispanic male with a
medical past history of an end-stage kidney disease of
uncertain etiology. His white blood cell count (WBC) was
elevated and measured at 23.15 × 103 per μL. Peripheral
blood smear showed marked lymphocytosis with nume-
rous atypical lymphoid cells including prolymphocytes,
smudge cells, normocytic normochromic anemia and
thrombocytopenia. The lymphoid-gated population con-
stituted 87% of total cells, and consisted of 2% T cells, 70%
B cells, and <2% NK cells (Figure 1A). Flow cytometry
showed co-expression of B-cell antigen (CD19) with CD5,
CD23, CD20, and ZAP70 expression. These results were
suggestive of CLL (Figure 1B).
Results
A complete chromosome analysis was not possible due
to low mitotic index. G-banded karyotype analysis of
available metaphase cells revealed an abnormal male
karyotype with an apparently balanced t(8;14)(q24.1;q32)
seen in 50% (6/12) of total cells examined (Figure 2).
Interphase FISH studies did not reveal IGH@-CCND1
rearrangement, but instead, an extra copy of IGH@-spe-
cific signal in 30.3% (91/300) of nuclei examined (data
not shown). In addition, deletions of the 13q14.3
(D13S319) (Figure 3A) and 11q22.3 (ATM) (Figure 3B) in
8% (24/300) and 78% (294/300) of cells were also observed,
respectively. Neither deletion of 17p13.1 (TP53) nor
trisomy 12 was detected (data not shown). Sequential
GPG-metaphase FISH studies were performed on the
same chromosome metaphase spread to determine
the clonality of the structural abnormalities seen in
our patient. Results showed that two different clones
exist in the peripheral blood of our patient: one with dele-
tion 13q14.3 (seen only in interphase nuclei in our study),Figure 1 Flow Cytometry Analysis in Peripheral Blood. A. The lymphoi
cells, 70% B cells, and <2% NK cells. B. Coexpression of CD19 B-cell antigenand another with concurrent deletion 11q (Figure 3C) and
t(8;14) (Figure 4D).
Further sequential FISH studies on 10 metaphase nu-
clei using the IGH@ break apart probe showed splitting
or rearrangement (1Y1G1R), with the 5’-IGH@ (green)
translocated on chromosome 8q24.1 and the 3’-IGH@
(red) retained on 14q (Figure 4A,B) in all cells examined.
The IGH@-MYC fusion (Figure 4C) and MYC break
apart (Figure 4D) probes revealed atypical abnormal sig-
nal patterns in all 10 cells examined on derivative
8q24.1: one green (5’-IGH@) and no red (deletion at
least 400 Kb upstream of 5’-MYC-3’); and, on derivative
14q32: one yellow (relocation of 5’-MYC-3’ and its flank-
ing regions adjacent to 3’-IGH@). The estimated loca-
tion of the translocation breakpoint upstream of 5’-MYC
was determined by in silico mapping (Figure 5) by deter-
mining the base pair coordinates in the UCSC Genome
Browser (hg19) of the STS markers mapped upstream of
5’-MYC-3’ (Abbott Vysis FISH probes website). We
based our calculations on the Spectrum Orange of the
MYC break apart probe, the farthest probe from 5’ of
MYC (as compared to the MYC probe in the IGH-MYC
fusion probe). The estimated distance of the transloca-
tion breakpoint (STS marker WI-1302) from 5’of MYC
is at least 400 Kb (bp 128,354,420-128,747,680). This
interval includes two RefSeq genes: POU5F1B (POU
class 5 homeobox 1B), an intronless gene that encodes
for a transcription factor (1.6 Mb; bp 128,427,857-
128,429,441) and a gene with no known function,
LOC727677 (38.8 Kb; bp 128,455,595-128,494,384). It
also includes the SNPs implicated in several cancer
types, rs1447295 (Region 1), rs16901979 (Region 2) and
rs6983267 (Region 3) [26] and CLL SNP rs2456449 [28].
SNP CMA refined the 11q22.3 deletion breakpoints
detected by FISH. Results showed a 7.1 Mb heterozygousd gated population constitutes 87% of total cells, and consists of 2% T
with CD5, CD23, CD20, and ZAP70, findings characteristic of CLL.
Figure 2 G-Banding karyotype of our patient’s peripheral blood reveals an apparently balanced t(8;14)(q24.1;q32).
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11q22.3q23.3(107,888,769-115,016,307)x1 (data not shown).
It deleted 62 RefSeq genes including ATM (ataxia telangi-
ectasia mutated), a gene that encodes for a cell cycle check-
point phosphorylating kinase that functions for regulating
proteins for tumor suppression, checkpoint, DNA repair
and maintenance of genome stability [32]. In addition, a
455 Kb heterozygous copy number loss on 14q32.33 was
also detected; arr 14q32.33(106,530,533-106,985,955)x1, de-
leting two gene fragments or non-protein coding genes of
no known function, LINC00226 and LINC00221 (data not
shown) [32]. CMA did not detect a microdeletion within or
surrounding the MYC locus despite its removal from der
8q24.1 locus. This suggests that there was no net gain or
loss despite the unbalanced rearrangements detected by
FISH. In a lesser extent, a 61 Kb gain on 8q24.12 was
detected, but found to be unreportable with further in silico
investigations. There were no clinically relevant gains or
losses detected on chromosomes 12, 13 and 17.
According to the ISCN [33], the overall findings








As mentioned above, deletion 13q14.3 and deletion
11q22.3 with t(8;14), detected by interphase and sequentialmetaphase FISH studies, are found as two different
abnormal clones, indicative of mosaicism. CMA failed
to detect gains or losses on 13q, since it only accounts for
8% of the total cell population, a number way below the
detection limit (10-30%) of either SNP or BAC microar-
rays [30].
Immunohistochemistry studies using specific MYC anti-
bodies did not detect any staining in our patient’s sample,
suggestive of absence of MYC activation (Figure 6A). A
strong positive staining for MYC was detected for the
positive control sample (Figure 6B).
Discussion
Our patient’s clinical, morphological and immunopheno-
typic features are consistent with the diagnosis of CLL.
Although complex cytogenetic findings including t(8;14)
usually confers poor prognosis in CLL, a consistent
genotype and phenotype correlation remains an unre-
solved issue. Our patient’s case exhibits an unreported
rearrangement involving IGH@ and MYC loci with ab-
sence of MYC expression.
In our patient, the FISH signal patterns detected are
unique from those previously reported in CLL cases with
atypical rearrangements and an apparently balanced t(8;14).
These include a cryptic deletion on 8q24.1 including MYC
[6,8], gain of an extra copy of MYC (+MYC) [4,5,29], or
deletion of IGH@, usually 5’ [3,4,6,30,31]. Although a
deletion of the MYC-specific signal on der 8q24.1 locus
was also observed in our patient using IGH-MYC fusion
probe (1Y2G1R), it is not identical to the reported deletion
Figure 3 Interphase and Sequential Metaphase FISH in our Patient’s Peripheral Blood using our CLL Panel. A-B: Interphase Nuclei FISH
detects: (A) deletion of 13q14.3 (D13S319) (2G1R2A), and (B) deletion of 11q22.3 (2G1R). The signal patterns for chromosome 12 centromere,
13q34 and 17p13.1 are normal. C-D: Sequential FISH on the metaphase cell with t(8;14) using: (A) ATM (green)/TP53 (red) specific probes reveals a
loss of one ATM signal (2G1R), and (B) with 13q14.3/13q34 specific probes did not reveal a deletion of 13q14.3 in this cell. These findings indicate
two separate abnormal clones, one with t(8;14) and 11q deletion, and another with 13q14.3 deletion.
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did not show splitting of signals and no concomitant dele-
tion of a 1.6 Mb segment including the MYC locus.
Instead, it showed two unsplit MYC probes (yellow) on
the normal chromosome 8 and on der 14q32. We inter-
preted these findings as an atypical rearrangement never
reported elsewhere, with the 5’-MYC-3’ removed from the
8q24.1 locus at a breakpoint at least 400 Kb upstream of
its 5’ region. We also showed that this deleted region is
relocated to the 14q32 locus and apposed to the 3’-IGH@
locus. Neither gain of MYC nor deletion of the 5’-IGH@
locus was observed by FISH or CMA in our case. We
have exhaustively searched the available literature and
did not find any cases similar to the signal patterns
reported on here.
To the best of our knowledge, expression levels of
MYC and its correlation to disease progression have notbeen established in CLL with t(8;14), with or without
MYC translocations [4,6,7]. MYC expression is generally
at low levels in CLL [23], and similar in groups with
either bad or good prognosis [34]. Increased expression
even without MYC rearrangement has also been
described in CLL with malignant Richter transformation
and other higher risk cases for CLL progression [10].
Although, high levels of MYC are expressed as a result
of the t(8;14) and its variant translocations in Burkitt’s
lymphoma and in some other B-cell malignancies in-
cluding DLBCL and plasma cell myeloma, these translo-
cations may not necessarily lead to increased expression
of MYC in CLL [4,6,7]. These variable findings of
MYC expression are most likely dependent on specific
disruptions of regulatory regions, or characteristic gen-
omic translocation breakpoints either at the MYC or
IGH@ locus.
Figure 4 Further Examination of the Rearrangement Involving the MYC and IGH@ Loci using Sequential Metaphase FISH in our
Patient’s Peripheral Blood. A: G-Banding metaphase spread showing an apparently balanced t(8;14)(q24.1;q32). B: The IGH@ break apart probe
reveals splitting of signals (1Y1G1R) indicative of rearrangement, with 5’-IGH@ relocated to der 8q and 3’-IGH@ retained on der 14q. C: The IGH-
MYC fusion probe shows 1Y2G1R2A, fusion of MYC-IGH der 14q32 (yellow), and deletion of MYC on der 8q24.1 (green, no red). It also shows
normal signal patterns for the other chromosome 8 (aqua for centromere and red for MYC), and chromosome 14 (green). D: The MYC break apart
probe detects 2Y signals, one on normal chromosome 8 and the other is removed from der 8q24.1 and relocated to der 14q32. These findings
suggest that there is neither splitting of signals, or a deletion in between the red and green signals.
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the MYC -deregulatting product, while the reciprocal
IGH-MYC fusion at 8q24.1 locus is transcriptionally si-
lent [14,35]. Despite the typical juxtaposition, overall
MYC expression in some CLL cases remains within the
normal range [20], or overexpressed through processes
other than translocations [9]. It has been reported that
the location of the genomic breakpoint influences MYC
expression, with highest level when involving Class I
breakpoints [15,24]. The absence of Myc expression in
our patient is most likely due to the atypical MYC-IGH
fusion on der 14q32, with a Class III breakpoint (at least
400 Kb upstream of MYC) [16].
The previously reported “gene desert” region upstream
of MYC extends up to about 629 Kb [26] and includes
genes and SNPs. Genome-wide association studies(GWAS) have shown the gene POU5F1B and several
genetic variants or SNPs (Regions R1, R2, R3) (Figure 5)
that are risk factors for various cancers including CLL
exist in this region [26-28,36-38]. The strongest evidence
for risk or genetic susceptibility in CLL or monoclonal
B-cell lymphocytosis is rs2456449 (8q24.21) [28,38]. In
our patient, the breakpoint that we suggested (at least
400 Kb) is within this interval and includes POU5F1B,
and SNPs R1 and R2. POU5F1B is one of the two RefSeq
genes within the breakpoint on 8q24.1 and 5’-MYC, is
the most adjacent. Although it is not yet well studied,
few reports described it as a pseudogene or a gene that
encodes for a weak transcription factor that may play a
critical role in stem cell pluripotency, eye development
and carcinogenesis [36,37,39]. At the present time, there
are no reports of a specific fusion involving 5’-POU5F1B
Figure 5 In Silico Mapping of the Translocation Breakpoint Upstream of 5’-MYC-3’ Reveals a Class III Breakpoint and a Region that
Contains SNPs associated with Susceptibility Risk Loci for different types of cancer including CLL, prostate, colorectal, bladder, or
breast cancer. The farthest probe upstream of 5’ of MYC is the Spectrum Orange of the MYC break apart probe (upper panel) (adopted from
Abbott Vysis website for FISH probes). We plotted the base coordinates for WI-1203 STS marker and the 5’ of MYC (see inlet) into the UCSC
Genome Browser (hg19) and determine the distance, RefSeq genes (POUF51B and LOC727677), STS markers and SNPs within this interval. The
translocation breakpoint (with lightning icon) is centromeric of WI-1203 and about ~400 Kb upstream of 5’-MYC, a Class III breakpoint. We
extended the breakpoint further upstream to show ~629 Kb region containing SNPs in different regions of the interval (R1, R2, R3 and CLL) that
confer susceptibility risks for cancer [26,28].
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breakpoint in our patient is further upstream, however, the
paucity of available cells made it impossible for further
characterization. In Figure 5, we extended the suggested
breakpoint further upstream, from ~400 Kb to ~600 Kb, to
include the farthest reported cancer-associated SNP (Re-
gion 2: rs16901979) and CLL SNP (rs2456449). To date,
the genotype phenotype correlation underlying these asso-
ciations remains unclear. However, it has been suggested
by reported expression studies that MYC expression is
influenced by such SNPs variants by altering its transcrip-
tion regulation and amplification [40]. Despite such pleth-
ora of reports, replication of these findings and elucidation
of its physiologic function and clinical significance remain
an area of thorough investigation. Further in vivo and
in vitro functional studies are needed to show consistent
association of risk allele status andMYC expression levels.On the other hand, transcription at the IGH@ locus is
controlled by enhancers elements spread out as wide as
2.5 Mb of the locus [12], and it contains regulatory ele-
ments necessary not only for MYC activation but also
the promotion of translocation [13]. CMA detected a
455 Kb copy number loss on chromosome band
14q32.2, not detected by FISH since the probe used was
outside of this region. It is still a possibility, that the de-
letion in our patient may have removed some of the
regulatory elements within this interval somehow affect-
ing the regulation of Myc expression. No regulatory ele-
ments or high conservation data was seen in the UCSC
Genome Browser. This microdeletion has been reported
in other CMA studies of CLL patients using BAC-based
array CGH, with some of the cases exhibiting the same
findings as ours, i.e. with no IGH@ deletion by FISH
[30]. It is still unclear whether this microdeletion is a
Figure 6 Immunohistochemistry using human anti-MYC
antibody. A. Positive MYC expression on a positive control.
B. Negative MYC expression in our patient’s blood smear.
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of frequent mutation and recombination, or it exhibits
some susceptibility risks for CLL [3,24,31,41].
About 20% of patients with CLL show ATM deletion,
an anomaly also seen in almost all cancer, and is usually
associated with an adverse outcome [1,4,31]. The collab-
oration of ATM and MYC in normal cell proliferation
via an ATM-dependent pathway is well established.
When deleted, ATM loses its protective checkpoint
function leading to MYC-induced oncogenesis [4,42].
This indicates that MYC alone is not capable of trans-
forming lymphoid cells into neoplasia [4]. The ATM de-
letion and removal and relocation of MYC observed in
our patient may explain the lymphomagenesis, but not
necessarily the absence of Myc expression.
Given the limitations of this case report, we suggest that
comprehensive retrospective studies in CLL patients should
be performed to characterize the suggested ~400 Kb break-
point and the region further upstream by sequential meta-
phase BAC FISH mapping since CMA does not detect the
removal and relocation of an intact MYC locus. It is also
possible that the absence of Myc expression is a false nega-
tive result given the specificity of immunostaining which isbelow 100%, and about 17% of cases may be overlooked for
MYC rearrangements using this technique [43]. A more ac-
curate quantitative approach such as RT-qPCR is recom-
mended. Since variability in MYC breakpoints could still
result in similar MYC expression [44], possibly due to flex-
ible DNA looping [43,45], reporter expression studies are
needed to better understand the clinical impact and signifi-
cance of long distance deregulation in in loci with atypical
MYC rearrangement.
This paper presents an unreported atypical rearrange-
ment involving the IGH@ and MYC loci detected by
FISH, adding to the burgeoning cytogenetic data on CLL
patients with atypical t(8;14). It also highlights the Class
III translocation breakpoint upstream of MYC, including
the cancer and CLL-associated SNPs within the interval.
This report also provides important and promising find-
ings for further studies correlating Myc expression with
a specific type of genomic translocation breakpoint or
copy number variants in CLL and in other B-cell disor-
ders. Lastly, overall findings in our report highlight the
utility of karyotype analysis, interphase and sequential
metaphase FISH studies, CMA, and other molecular
tools in approaching the diagnosis and prognosis of CLL
in a more comprehensive manner.
Materials and methods
Conventional GPG-banded chromosomal analysis was
performed on peripheral blood lymphocytes that were
cultured for 48 and 72 hours with and without poke-
weed mitogen stimulation, following standard cytogenet-
ics protocols. The karyotypes were described according
to the ISCN 2009 nomenclature [33].
Initial FISH studies were performed on interphase
cells using CLL panel probes (Abbott Molecular, Des
Plaines, Illinois) specific for centromere 12, IGH@
break apart or IGH@-CCND1 fusion, and chromo-
some loci 13q14.3 (D13S319)/13q34, 11q22.3 (ATM)
and 17p13.1 (TP53). Sequential GPG-metaphase FISH
studies were performed using IGH-MYC fusion (with
centromere 8-specific probe), and break apart probes for
the IGH@ and MYC loci.
Chromosome microarray analysis was performed on
DNA sample from 48-hr culture of peripheral blood
lymphocytes. DNA was extracted from Carnoy’s fixed pellet
cells Qiagen DNA extraction kit (Valencia, CA). DNA con-
centration and quality was checked using Nanodrop
(Life Technologies, Carlsbad, CA) and gel electrophoresis,
respectively. Whole genome chromosome SNP microarray
was performed to assess for imbalances (i.e. gain or losses)
in the genomic DNA sample tested. The assay compared
the patient’s DNA to a reference set from 380 normal con-
trols (284 HapMap and 96 Affymetrix reference), using the
Genome-Wide SNP Array CytoScan HD. This array plat-
form contains 2.6 million markers for Copy Number
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genotype SNPs and 1.9 million are non–polymorphic
probes, for the whole genome coverage. The analysis was
performed using the chromosome analysis suite (ChAS),
version CytoB-N1.2.2.271(r4615). Oligonucleotide probe in-
formation is based on the 37 build of the Human Genome
(UCSC Genome Browser, http://genome.ucsc.edu/cgi-bin/
hgGateway, hg19, February 2009).
FFPE sections (4 μm thick) were stained for Myc
using rabbit monoclonal human anti-Myc antibody
(catalog #1472-1, Epitomics, Inc., Burlingame, CA, USA).
Heat-induced epitope retrieval was accomplished by using
ER1 for 20 min. Endogenous peroxidase was blocked
using hydrogen peroxide. The slide was incubated in the
primary antibody Myc for 30 min, followed by incubation
in a post-primary 3,3-diaminobenzidine for 10 min, poly-
mer 3,3-diaminobenzidine for 10 min, and chromogen
3,3-diaminobenzidine for 10 min. Subsequently, slide was
incubated with post-primary alkaline phosphatase for
20 min, polymer alkaline phosphatase for 30 min, and fast
red for 20 min. The nuclei were counterstained with
hematoxylin and the slide was then dehydrated, cleared in
xylene, and coverslipped. Appropriate positive controls
were used.
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